In this issue:
Subcutaneous vs. transvenous defibrillator therapy
Benefits of disease-modifying pharmacological therapies in HFREF
Sacubitril/valsartan vs. putative placebo in HF across the EF range
DAPA-HF: dapagliflozin effects according to background HF/diuretic therapy
Lung ultrasound-guided HF therapy
Baroreflex activation therapy in HFREF
Upright Cheyne-Stokes respiration in HF
Therapies for HFREF with central sleep apnoea
Outcomes for hypertrophic cardiomyopathy with LV systolic dysfunction
Please login below to download this issue (PDF)